EVACS Trial (Evolocumab in Acute Coronary Syndrome)

Dr. Thorsten Leucker,  Assistant Professor of Medicine in the Division of Cardiology, Department of Medicine at the Johns Hopkins University School of Medicine discusses a study, EVACS (Evolocumab in Acute Coronary Syndrome) evaluating a hospital-based intervention option in ACS patients that was published in the American Heart Association’s journal, “Circulation”.  The study examined LDL-C reduction in non-ST-elevation myocardial infarction (NSTEMI) patients that met certain criteria. 

Read More

Obsidian Therapeutics – Cell and Gene Therapy

Dr. Paul Wotton, CEO of Obsidian Therapeutics, discusses Obsidian’s platform, cytoDRiVE™, that regulates protein levels in cell and gene therapies, creating an “operating system” for living drugs. This means that now, and for the first time, physicians will be able to control genetically-engineered cells’ biologic activity to increase efficacy and reduce toxicity, using easily accessed generics and other FDA-approved drugs.

Read More

Guardant Health – Radius Health Partner for Breast Cancer Therapy

Returning guest, Daniel Simon, SVP, BioPharma Business Development at Guardant Health, a leading precision oncology company discusses a strategic collaboration with Radius Health for the commercialization and use of the Guardant360® CDx  liquid biopsy companion diagnostic for elacestrant (RAD1901), an investigational therapy being studied for the treatment of advanced breast cancer in combination with hormone therapy.

Read More

Health Security and Smallpox Potential

Dr. Phillip Gomez, Ph.D., CEO at SIGA Technologies, Inc., discusses how the field of Health Security has transformed after the anthrax attacks in the United States in late 2001.  He also talks about the potential for a smallpox bioterror attack and how would it compare with the current COVID-19 pandemic. 

Read More